-       Report 
   - October 2025
    -  196 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - November 2025
    -  371 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - April 2025
    -  185 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                   -       Report 
   - October 2025
    -  180 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  183 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €4029EUR$4,490USD£3,536GBP 
                -       Report 
   - November 2025
    -  334 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  281 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                -       Report 
   - November 2025
    -  371 Pages 
    Global
   
   From       €5249EUR$5,850USD£4,607GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1077EUR$1,200USD£945GBP 
      €1346EUR$1,500USD£1,181GBP 
                -       Report 
   - June 2025
    -  150 Pages 
    Global
   
   From       €2422EUR$2,699USD£2,126GBP 
                  -       Report 
   - August 2025
    -  90 Pages 
    North America
   
   From       €2479EUR$2,763USD£2,176GBP 
      €2916EUR$3,250USD£2,560GBP 
                -       Report 
   - September 2023
    -  150 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                -       Report 
   - July 2022
    -  150 Pages 
    Global
   
   From       €2019EUR$2,250USD£1,772GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - May 2024
    -  128 Pages 
    Global
   
   From       €4957EUR$5,524USD£4,351GBP 
      €5832EUR$6,499USD£5,118GBP 
             
         The Muscle Spasm Drug market is a subset of the Central Nervous System Drugs market. It includes drugs used to treat muscle spasms, which are involuntary contractions of the muscles. These drugs are used to reduce pain and discomfort associated with muscle spasms, as well as to improve mobility. Commonly used muscle spasm drugs include muscle relaxants, antispasmodics, and anticonvulsants. These drugs are typically prescribed by a physician and are available in both oral and injectable forms.
The    Muscle Spasm Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Novartis, GlaxoSmithKline, Merck, and Sanofi. Other companies in the market include AbbVie, AstraZeneca, Teva Pharmaceuticals, and Mylan. Show Less   Read more